New trials, publications, preprints and grants on this target, month by month.
Trial
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
31 Jan 2027· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
31 Dec 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
1 Dec 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations
1 Dec 2026· PHASE2 · NOT_YET_RECRUITING· CTIS
Trial
ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
30 Nov 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
[Dedifferentiated solitary fibrous tumor of the kidney with RB1/p16 pathway abnormalities and TP53 mutation: report of a case].
8 Nov 2026· Zhonghua bing li xue za zhi = Chinese journal of pathology· PUBMED
Publication
NRF2 and mutant p53 separately regulate redox balance in esophageal squamous cell carcinoma through metabolic reprogramming.
6 Nov 2026· Cancer biology & therapy· PUBMED
Publication
Toxoplasma gondii GRA16-induced apoptosis in KRAS-mutant colorectal cancer cells is linked to coordinated p53 and PP2A-B55 signaling.
6 Nov 2026· Parasites, hosts and diseases· PUBMED
Publication
Sirt1 Modulates p53‑Acetylation‑Dependent Yy2‑Elf‑1‑Associated NLRP3‑Relevant Signaling in CUMS‑Evoked Aggravated Alzheimer's Disease‑Related Phenotypes.
5 Nov 2026· Brain research bulletin· PUBMED
Publication
Statement of Retraction: DEP domain containing 1B (DEPDC1B) exerts the tumor promoter in hepatocellular carcinoma through activating p53 signaling pathway via kinesin family member 23 (KIF23).
5 Nov 2026· Bioengineered· PUBMED
Publication
Statement of Retraction: Long non-coding RNA p53 upregulated regulator of p53 levels (PURPL) promotes the development of gastric cancer.
5 Nov 2026· Bioengineered· PUBMED
Publication
Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53, STAG2, and CDKN2A Alterations.
4 Nov 2026· Journal of clinical oncology : official journal of the American Society of Clinical Oncology· PUBMED
Publication
Aflatoxin B1 (AFB1) Accelerates the Pathological Process of Hepatic Aging by Hijacking the Aryl Hydrocarbon Receptor (AHR) Signaling Pathway.
4 Nov 2026· Journal of agricultural and food chemistry· PUBMED
Publication
Crocin attenuates dopaminergic neuronal injury in 6-OHDA-induced PD rats: Associations with mitochondrial protection and p38/p53 signaling.
4 Nov 2026· Brain research bulletin· PUBMED
Publication
Omega-3 DHA Targets P53-Mutant CRC Stem-like Cells via Membrane Disruption, Modulation of Differential Marker Genes, and Suppression of Self-Renewal Capacity.
4 Nov 2026· International journal of toxicology· PUBMED
Publication
Impacts of mutation accumulation and order on tumor initiation revealed by engineered murine colorectal cancer organoids.
3 Nov 2026· eLife· PUBMED
Publication
A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells.
3 Nov 2026· Cancer research· PUBMED
Publication
TP53-Mutated Preneoplastic Colonies, Adaptive Immune Response, and Risk for Lung Cancer and COPD.
2 Nov 2026· Cancer prevention research (Philadelphia, Pa.)· PUBMED
Trial
Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome
1 Nov 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
Non-Small Cell Lung Carcinoma With Bilayered Architecture and TP53 Alteration: A Diagnostic Pitfall and a Potential Distinct Entity.
1 Nov 2026· Thoracic cancer· PUBMED
Publication
Short-Course Selinexor and Decitabine With Homoharringtonine-Based Chemotherapy for Pretransplant Cytoreduction in TP53-Altered Complex-Karyotype Myeloid Neoplasms.
1 Nov 2026· Hematological oncology· PUBMED
Publication
ASO Visual Abstract: KRAS and TP53 Circulating Tumor DNA are Prognostic in Localized Pancreatic Cancer.
1 Nov 2026· Annals of surgical oncology· PUBMED
Publication
Diagnostic and prognostic significance of p16, p53, and PD-L1 expression in cervical lesions: A combined immunohistochemical, histopathological, and radiological correlation study.
30 Oct 2026· Indian journal of pathology & microbiology· PUBMED
Publication
Comparative immunohistochemical analysis of survivin, p53, and Ki-67 expression in cervical squamous intraepithelial lesions and squamous cell carcinoma.
30 Oct 2026· Indian journal of pathology & microbiology· PUBMED
Publication
TP53 dysregulation in Wilms tumor: an integrative clinico-genomic analysis and its prognostic implications.
30 Oct 2026· Molecular genetics and genomics : MGG· PUBMED
Publication
Resveratrol partially restores the expression of the clock genes Per1 and Bmal1 in the suprachiasmatic nucleus of scopolamine-induced Alzheimer's rat model.
29 Oct 2026· Experimental brain research· PUBMED
Publication
ATR inhibitors and gemcitabine synergize to induce cell death in TP53-mutant, ATRX-wildtype uterine leiomyosarcoma.
29 Oct 2026· Molecular cancer therapeutics· PUBMED
Publication
Editorial Expression of Concern: Cell death by the quinoxaline dioxide DCQ in human colon cancer cells is enhanced under hypoxia and is independent of p53 and p21.
28 Oct 2026· Radiation oncology (London, England)· PUBMED
Publication
USP25 promotes ferroptosis in diabetic retinopathy by deubiquitinating p53 and suppressing the GPX4/SLC7A11 axis.
27 Oct 2026· Journal of diabetes investigation· PUBMED
Publication
USP22-mediated phagocytic evasion promotes immune escape in TP53-inactivated hepatocellular carcinoma.
27 Oct 2026· Clinical and molecular hepatology· PUBMED